Here are 17 updates to know from orthopedic giant Zimmer Biomet’s busy 2025, as reported by Becker’s this year:
- Zimmer Biomet and OneStep, a digital fall and mobility intelligence platform, entered an exclusive collaboration for mobility data.
- The company’s third quarter sales grew 9.7%.
- Zimmer Biomet earned the FDA’s Breakthrough Device Designation for its iodine-treated total hip replacement system.
- Zimmer Biomet and Paragon 28 commercially launched two new foot and ankle trauma products.
- Zimmer Biomet completed its $177 million acquisition of Monogram Technologies, an orthopedic robotics company.
- The organization received approval from the Pharmaceutical and Medical Devices Agency in Japan for the iTaperloc Complete and iG7 Hip System.
- Zimmer Biomet filed a lawsuit against Deloitte, accusing the consulting firm of mismanaging a resource planning software system.
- Orthopedic surgeons Jonathan Vigdorchik, MD, and Anand Murthi, MD, were named as advisors of Zimmer’s orthopedic businesses.
- Second quarter sales for Zimmer Biomet surpassed $2 billion.
- Medical technology company Treace Medical Concepts filed a lawsuit against Zimmer Biomet and Paragon 28 alleging infringements of four patents.
- Ivan Tornos, the company’s CEO, joined the Orthopaedic Research and Education Foundation board.
- Egypt’s Ministry of Health and Population and Zimmer Biomet signed a cooperation agreement.
- Zimmer Biomet’s revenue in the first quarter of 2025 was mostly flat with a 1.1% increase year-over-year.
- Zimmer Biomet completed its acquisition of Paragon 28, a medical device company in the foot-and-ankle orthopedic sector.
- The company has plans to launch three Rosa robotic indications in the next 18 months.
- Kristen Cardillo was appointed senior vice president and chief communications officer.
- John Sperling, MD, of Rochester, Minn.-based Mayo Clinic performed the first cases with Zimmer Biomet’s OsseoFit stemless shoulder system.
